<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464670</url>
  </required_header>
  <id_info>
    <org_study_id>EBOV-001</org_study_id>
    <nct_id>NCT02464670</nct_id>
  </id_info>
  <brief_title>Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers</brief_title>
  <official_title>Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Defense Advanced Research Projects Agency</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered&#xD;
      intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well&#xD;
      tolerated and immunogenic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the safety, tolerability, and immunogenicity of the DNA vaccine,&#xD;
      INO-4212 and its components INO-4201 and INO-4202 in healthy volunteers. INO-4201 contains&#xD;
      the DNA sequence that codes for past Ebola Zaire virus outbreak strains, and INO-4202&#xD;
      contains the DNA sequence that codes for the current Ebola virus outbreak strain. When given&#xD;
      together, the DNA vaccine is called INO-4212 and contains the DNA sequence of both the&#xD;
      previous and the current outbreak strain. Another ingredient called INO-9012 which contains&#xD;
      the DNA sequence for interleukin-12, will be given in a subset of subjects to help boost the&#xD;
      body's immune response when given with the vaccine.&#xD;
&#xD;
      Following administration of vaccine, a specialized medical device, CELLECTRA®, will deliver&#xD;
      brief electrical pulses in a process known as electroporation (EP), to help move more DNA&#xD;
      into cells more efficiently. The study will evaluate whether INO-4212 and its components may&#xD;
      be able to generate protective immunity against Ebola Zaire, evaluate the relative ability of&#xD;
      IM versus ID administration to elicit immune responses and evaluate whether vaccine&#xD;
      administered with INO-9012 can generate greater immune responses.&#xD;
&#xD;
      The Ebola vaccine under study will be tested in approximately 240 healthy adult volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 24, 2018</completion_date>
  <primary_completion_date type="Actual">May 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>In Part II only (Groups 3A and 3B), the current strength of the device will be masked from the study team administering the procedure and participant. All IP assignments will be open label and unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment (Composite of multiple measures: adverse events, pain (VAS), lab abnormalities, changes in vital signs)</measure>
    <time_frame>Screening through up to 60 weeks following the first dose</time_frame>
    <description>Composite of multiple measures consist of:&#xD;
Frequency and severity of all adverse events&#xD;
Local pain immediately and at 5 and 10 minutes after Study Treatment/EP using a visual analog scale from 0 to 10, with 0 representing &quot;No Pain&quot; and 10 representing &quot;Worst Pain&quot;&#xD;
Frequency and severity of local and systemic events for at least 7 days after Study Treatment/EP&#xD;
Frequency and severity of laboratory abnormalities&#xD;
Changes in vital signs (blood pressure, heart rate, respiratory rate, temperature)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunology Assessment</measure>
    <time_frame>Screening and at select points up to 60 weeks following the first dose</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including:&#xD;
Breadth and magnitude of antigen specific ELISA&#xD;
Breadth and magnitude of neutralizing antibodies&#xD;
Breadth and magnitude of antigen specific cellular immune responses as determined by&#xD;
Interferon-gamma (IFN-γ) ELISpot&#xD;
Intracellular Cytokine Staining (CTL phenotype, Lytic granule loading, Granzyme B killing of target cells)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Assessment</measure>
    <time_frame>Screening and at select points up to 60 weeks following the first dose</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including:&#xD;
Differences in immune response between ID delivery of INO-4201 followed by EP compared to IM delivery of INO-4201 followed by EP&#xD;
Differences in immune response between IM delivery of INO-4212 in combination with INO-9012 followed by EP compared to IM delivery of INO-4212 alone followed by EP&#xD;
Differences in immune response between ID delivery of INO-4201 in combination with INO-9012 followed by EP compared to ID delivery of INO-4201 alone followed by EP&#xD;
Differences in immune response between 2 doses or 3 doses of INO-4201 alone or in combination with INO-9012 administered ID followed by EP&#xD;
Differences in immune response between either 1 mg or 2mg total of INO-4201 alone or in combination with INO-9012 administered ID followed by EP&#xD;
Differences in immune response between ID delivery of INO-4201 followed by EP with either 0.2 A or 0.1 A&#xD;
Perception of injection among subjects enrolled in Part II</description>
  </other_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Ebola Vaccine</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 IM + EP, 2 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4202 IM + EP, 2 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 ID + EP 0.2A, 2 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4212 IM + EP, 4 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 ID + EP 0.2A, 1 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 ID + EP 0.2A, 2 mg, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 ID + EP 0.2A, 1 mg, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Group 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 ID + EP 0.2A, 2 mg, 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Group 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INO-4201 ID + EP 0.1A, 2 mg, 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-4201</intervention_name>
    <description>INO-4201 delivered IM followed by Electroporation</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-4202</intervention_name>
    <description>INO-4202 delivered IM followed by Electroporation</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-4201</intervention_name>
    <description>INO-4201 delivered ID followed by Electroporation</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_label>Part II: Group 3A</arm_group_label>
    <arm_group_label>Part II: Group 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-4212</intervention_name>
    <description>INO-4212 delivered IM followed by Electroporation</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-4212 + INO-9012</intervention_name>
    <description>INO-4212 + INO-9012 delivered IM followed by Electroporation</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-4201 + INO-9012</intervention_name>
    <description>INO-4201 + INO-9012 delivered ID followed by Electroporation</description>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-50 years;&#xD;
&#xD;
          -  Able to provide consent to participate and having signed an Informed Consent Form&#xD;
             (ICF);&#xD;
&#xD;
          -  Able and willing to comply with all study procedures;&#xD;
&#xD;
          -  Women of child-bearing potential who are in a relationship that could result in&#xD;
             pregnancy agree to either remain sexually abstinent, use medically effective&#xD;
             contraception (oral contraception, barrier methods, spermicide, etc.) or have a&#xD;
             partner who is sterile from enrollment to 3 months following the last injection; OR,&#xD;
             sexually active men who are considered sexually fertile must agree to use either a&#xD;
             barrier method of contraception during the study, and agree to continue the use for at&#xD;
             least 3 months following the last injection, or have a partner who is permanently&#xD;
             sterile or unable to become pregnant;&#xD;
&#xD;
          -  Normal screening ECG or screening ECG with no clinically significant findings;&#xD;
&#xD;
          -  Screening laboratory (Complete blood count (CBC), serum electrolytes, blood urea&#xD;
             nitrogen (BUN), creatinine (Cr), glucose, ALT, CPK, urinalysis) grade 0-1 within 30&#xD;
             days prior to administration of study treatment;&#xD;
&#xD;
          -  No history of clinically significant immunosuppressive or autoimmune disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Administration of an investigational compound either currently or within 30 days of&#xD;
             first dose;&#xD;
&#xD;
          -  Previous receipt of an investigational product in an interventional trial for the&#xD;
             treatment or prevention of Ebola (exceptions: verified receipt of placebo only or&#xD;
             participation in an observational study);&#xD;
&#xD;
          -  History of or positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or&#xD;
             any potentially communicable infectious disease as determined by the Principal&#xD;
             Investigator or Medical Monitor;&#xD;
&#xD;
          -  Positive serologic test for hepatitis C (exception: successful treatment with&#xD;
             confirmation of sustained virologic response);&#xD;
&#xD;
          -  Baseline creatinine greater than 1.5 (CKD Stage II or greater);&#xD;
&#xD;
          -  Chronic liver disease or cirrhosis;&#xD;
&#xD;
          -  Immunosuppressive illness including hematologic malignancy, history of solid organ or&#xD;
             bone marrow transplantation;&#xD;
&#xD;
          -  Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;&#xD;
&#xD;
          -  Prior major surgery or radiation therapy within 4 weeks of randomization;&#xD;
&#xD;
          -  Pregnant, breast feeding, or considering becoming pregnant;&#xD;
&#xD;
          -  Less than two acceptable sites exist for intramuscular or intradermal injection and EP&#xD;
             between use of the deltoid and lateral quadriceps muscles. A site for injection/EP is&#xD;
             not acceptable if there are tattoos, keloids or hypertrophic scars within 2 cm of the&#xD;
             injection/EP site.&#xD;
&#xD;
          -  Subject has significant acute or chronic medical illness if deemed by the practitioner&#xD;
             that electroporation treatment could negatively impact the illness&#xD;
&#xD;
          -  Subject has unstable or life-threatening cardiac disease (e.g. unstable angina, class&#xD;
             3 or higher congestive heart failure)&#xD;
&#xD;
          -  Subject has an acute or chronic bleeding or clotting disorder that would&#xD;
             contraindicate IM injections or use of blood thinners (e.g. anticoagulants or&#xD;
             antiplatelet drugs) within 2 weeks;&#xD;
&#xD;
          -  Subject has a cardioverter-defibrillator or pacemaker (to prevent a life-threatening&#xD;
             arrhythmia) that is located ipsilateral to the intended deltoid injection site (unless&#xD;
             deemed acceptable by a Cardiologist);&#xD;
&#xD;
          -  Subject has metal implant or implantable medical device within the electroporation&#xD;
             area;&#xD;
&#xD;
          -  Administration of any vaccine within 4 weeks of first dose;&#xD;
&#xD;
          -  Administration of any blood product within 3 months of first dose;&#xD;
&#xD;
          -  Current or anticipated concomitant immunosuppressive therapy (excluding inhaled,&#xD;
             topical skin and/or eye drop-containing corticosteroids, or low-dose methotrexate).&#xD;
             Systemic corticosteroids must be discontinued at least 4 weeks prior to first dose;&#xD;
&#xD;
          -  Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab,&#xD;
             etanercept;&#xD;
&#xD;
          -  Active military service personnel;&#xD;
&#xD;
          -  Prisoner or subjects who are compulsorily detained (involuntary incarceration) for&#xD;
             treatment of either a physical or psychiatric illness;&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements or assessment of immunologic&#xD;
             endpoints; or&#xD;
&#xD;
          -  Any illness or condition that in the opinion of the investigator may affect the safety&#xD;
             of the subject or the evaluation of any study endpoint.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott White, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS MRA</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, McMullan T, Jeong M, Roberts CC, Park YK, Boyer J, Broderick KE, Kobinger GP, Bagarazzi M, Weiner DB, Sardesai NY, White SM. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis. 2019 Jul 2;220(3):400-410. doi: 10.1093/infdis/jiz132.</citation>
    <PMID>30891607</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola</keyword>
  <keyword>Vaccine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

